MediFind

Find a Doctor

Amanda F. Cashen

Washington University
Oncology, Hematology, Internal Medicine
Female
Practicing approx. 21 years
Approx. age 47

Bio


Amanda Cashen is an Oncologist and an Internal Medicine specialist in Saint Louis, Missouri. She has been an author on 106 peer reviewed articles and participated in 19 clinical trials in the past 15 years. Dr. Cashen's top three areas of expertise are Acute Myeloblastic Leukemia with Maturation, Non-Hodgkin Lymphoma, and Acute Myeloblastic Leukemia without Maturation. She is licensed to treat patients in MO.

Contact

10 Barnes W Dr
Barnes Jewish W Co Siteman Cancer Ctr
Saint Louis, MO 63141, US

Latest Research


Latest Advance
Study
  • Condition: Chronic Lymphocytic Leukemia (CLL)
  • Journal: The New England journal of medicine
  • Treatment Used: Ibrutinib-Rituximab vs. Chemoimmunotherapy
  • Number of Patients: 529
  • Published —
This study evaluated the effectiveness of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL).
Latest Advance
Study
  • Condition: High-Risk Myelodysplasia and Older Patients with Acute Myeloid Leukemia
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant
  • Number of Patients: 63
  • Published —
The study compared addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia and older patients with acute myeloid leukemia.
Latest Advance
Study
  • Condition: Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Journal: Blood
  • Treatment Used: Duvelisib vs, Ofatumumab
  • Number of Patients: 319
  • Published —
This study compared duvelisib versus ofatumumab monotherapy for patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Latest Advance
Study
  • Condition: Relapsed Leukemia
  • Journal: Blood
  • Treatment Used: ALT-803
  • Number of Patients: 33
  • Published —
This study tested the safety and efficacy of using a novel ALT-803 IL-15 superagonist formulation to treat patients with leukemia that relapsed even after a stem cell transplant.

Clinical Trials


Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 48
  • Start Date: December 31, 2020
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed AML
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 36
  • Start Date: October 31, 2020
A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 36
  • Start Date: July 23, 2020
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 24
  • Start Date: April 7, 2020
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 165
  • Start Date: January 29, 2020
Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 20
  • Start Date: October 16, 2018
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 42
  • Start Date: July 31, 2017
A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 60
  • Start Date: January 30, 2017
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Clinical Trial
Procedure
  • Status: Recruiting
  • Study Type: Procedure
  • Participants: 50
  • Start Date: April 30, 2015
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Clinical Trial
Drug
  • Status: Recruiting
  • Study Type: Drug
  • Participants: 140
  • Start Date: August 11, 2014
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS

All Publications
View All


Publication
Study
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Published —
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Publication
Study
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Published —
A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma.

Contact

10 Barnes W Dr
Barnes Jewish W Co Siteman Cancer Ctr
Saint Louis, MO 63141, US

Affiliations

  • Barnes Jewish Hospital

Credentials

  • Graduate InstitutionWashington University School Of Medicine
    1999
  • Licenses
    Internal Medicine in MO
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.